You may find more results for this query on our sister sites: GenomeWeb and 360Dx.
Through this partnership, the companies hope to help oncologists make better testing and treatment decisions, as well as improve clinical trial matching.
The partners will apply whole-exome and whole-transcriptome analysis to evaluate two existing drugs for squamous cell carcinoma treatment.
With $6.5M in new funding, the Israeli bioinformatics startup is looking to open a US office as it builds relationships with pharma, cancer centers, and payors.
Formerly the data analytics division of CTCA, Vidence is supporting an immuno-oncology trial for BMS as it looks to grow its network of hospital partners.
The initial investment is led by Debiopharm, which will collaborate with the Israeli startup to accelerate discovery of biomarkers for oncology drug response.
The startup has exclusively licensed an integration engine from the University of Miami to augment its VIPER platform and improve trial recruitment specifically in precision oncology.
The bioinformatics vendor is customizing a multiomics health data platform to help pancreatic cancer researchers pursue new therapeutic targets.
With EMR upgrades, Penn and Rush now have structured genomic data informing clinical decision support in their precision oncology programs, but much work remains.
Informaticians from Georgetown and other major cancer centers expect their technology to bring precision oncology services to community hospitals and clinics.
Despite plenty of hype and some growing pains, artificial intelligence is starting to prove its value in academic and community cancer centers.